the immune response to hcv and hcv vaccine development
DESCRIPTION
The Immune Response to HCV and HCV Vaccine Development. Georg M. Lauer Gastrointestinal Unit Massachusetts General Hospital Harvard Medical School. No Conflicts of Interest. Dranoff , 2004. Dranoff , 2004. HCV Control and T Cells. HLA association studies - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/1.jpg)
The Immune Response to HCV and HCV Vaccine Development
Georg M. LauerGastrointestinal Unit
Massachusetts General HospitalHarvard Medical School
![Page 2: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/2.jpg)
No Conflicts of Interest
![Page 3: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/3.jpg)
Dranoff, 2004
![Page 4: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/4.jpg)
Dranoff, 2004
![Page 5: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/5.jpg)
HCV Control and T Cells
• HLA association studies HLA class I (incl. B27, B57 as in HIV) & class II
• GWAS (class II)• Chimpanzee CD8+ and CD4+ T cell depletion
associated with viral persistence • IFN- HCV specific CD8+ T cell responses are
temporally correlated with reduction in viremia after infection
Grakoui et. al, Science 2003, Shoukry et. al. J. Exp Med, 2003, Kim et. al. Gastroenterology 2011, Urbani et al Hepatology 2006, Thimme et al, J Exp Med 2001,David Thomas, in submission (GWAS)
![Page 6: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/6.jpg)
HCV-specific T-cell responses
①What happens during early HCV Infection?
②Correlates of protection
Breadth and vigor of HCV-specific T cell responses
T cell function
③The T cell road to HCV prevention?
![Page 7: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/7.jpg)
HCV-specific T-cell responses
①What happens during early HCV Infection?
②Correlates of protection
Breadth and vigor of HCV-specific T cell responses
T cell function
③The T cell road to HCV prevention?
![Page 8: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/8.jpg)
HCV Infection:Acute Infection to Chronicity
HCV Viral Load
ALT
![Page 9: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/9.jpg)
HCV Infection:Acute Infection to Chronicity
HCV Viral Load
ALT
![Page 10: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/10.jpg)
HCV Infection:Dichotomous outcome
Acute vs Chronic
A
CHCV Viral Load
ALT
20-30%
![Page 11: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/11.jpg)
HCV Infection:Outcome Determined within 24 Weeks
A
CHCV Viral Load
ALT
![Page 12: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/12.jpg)
HCV-specific T-cell responses
①What happens during early HCV Infection?
②Correlates of protection
Breadth and vigor of HCV-specific T cell responses
T cell function
③The T cell road to HCV prevention?
![Page 13: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/13.jpg)
Thimme et al. J Exp Med 2001
Acute HCV Infection:Adaptive Immune response
•Needle stick infections (known exposure)
•No adaptive immune responses before week 7
•ALT increase after immune response
![Page 14: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/14.jpg)
CD4 Responses in Early HCV Infection
Schulze zur Wiesch et al., J Exp Med 2012
A C
•Proliferative responses only in acute infection
•Usually targeting multiple HCV proteins
•Proliferative defect seen very early in chronic infection
•Long established observation (Gerlach 1999)
![Page 15: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/15.jpg)
Standard proliferation assay
Patient 05V with acute chronically evolving course:
short term culture (+exogenous rIl2)
CD4 Responses in Early HCV Infection
Schulze zur Wiesch et al., J Exp Med 2012
![Page 16: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/16.jpg)
CD4 Responses in Early HCV Infection
Schulze zur Wiesch et al., J Exp Med 2012
A C A C
Standard proliferative assay T Cell Lines with IL-2
![Page 17: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/17.jpg)
CD4 Responses in Early HCV Infection
Schulze zur Wiesch et al., J Exp Med 2012
A CAC
T Cell Lines with IL-2:Number of detected responses depends on time post infection, but only in chronic infection
![Page 18: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/18.jpg)
CD4 Responses in Early HCV Infection
Schulze zur Wiesch et al., J Exp Med 2012
Results from Cell Lines confirmed by HCV HLA Class II Tetramer analysis
Acute
Chronic
![Page 19: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/19.jpg)
HCV-specific CD4+ T-cell responses • Detectable in all subjects• No correlation between early breadth/vigor and outcome• Rapid contraction with viral persistence (in PBMC)• Early functional defect (proliferation) associated with viral
persistence• In persistent infection affected earlier and more
profoundly compared to CD8 responses• New technologies allow analysis of early T cell responses
in HCV – dichotomous outcome makes HCV unique model to define protective immunity
![Page 20: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/20.jpg)
Phases of Early HCV Infection/T Cell Response
A
C
1: “NOTHING”
No Adaptive Immunity Weeks 0 to 6/8
Is time of essence?
Role of innate immunity?
CD8 T Cell Response
CD4 T Cell Response
![Page 21: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/21.jpg)
Phases of Early HCV Infection/T Cell Response
A
C
2: “Emerging Response”
ALT RiseFollowed by HCV RNA Inflection
CD4/8 responses similar breadth and magnitude
CD4 proliferative defect
Other functional differences?
CD8 T Cell Response
CD4 T Cell Response
![Page 22: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/22.jpg)
Phases of Early HCV Infection/T Cell Response
A
C
3: “Battle”
HCV RNA Fluctuations
Emerging differences in CD4/8 response (magnitude/function)
Beginning T cell exhaustion?Early viral escape mutations?
CD8 T Cell Response
CD4 T Cell Response
![Page 23: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/23.jpg)
Phases of Early HCV Infection/T Cell Response
A
C
4: “Resolved/Chronic”
Marked differences in T cell numbers/phenotype/function
Differences cause or effect of viral control/persistence?
Differences reversible? (Immunotherapy)
CD8 T Cell Response
CD4 T Cell Response
![Page 24: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/24.jpg)
Phases of Early HCV Infection/T Cell Response
A
C
6 to 24 weeks post infection
Most important phase to study HCV T cell responses (but most “acute” studies are later)
HCV could/should be a unique model to define protective immunity
CD8 T Cell Response
CD4 T Cell Response
![Page 25: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/25.jpg)
HCV-specific T-cell responses
①What happens during early HCV Infection?
②Correlates of protection
Breadth and vigor of HCV-specific T cell responses
T cell function
③The T cell road to chronic HCV prevention?
![Page 26: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/26.jpg)
HCV- Can we make an effective vaccine?
• Challenges parallel to HIV– Correlates of protection not exactly known– Highly diverse virus– Unsafe to use live attenuated or killed virus– Current focus is to use vectors to deliver viral
antigens in a system that induces robust innate and adaptive immune responses
• Preexisting vector immunity limits responses
![Page 27: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/27.jpg)
Preventing pre-existing anti-vector immunity from limiting vaccine efficacy
• Okairos search for novel adenoviral strains in chimpanzees worldwide
• Goals: Discover adenoviral vectors that are• Highly immunogenic• Easily manufactured to high titers• Not stimulating cross reactive immunity
(humans rarely exposed)• Success:
• Adenoviruses derived from chimpanzees (ChAd) differ from human adenovirus primarily in hexon (surface) proteins, making Ab cross reactivity low
• many are highly immunogenic
Folgori et al. Nature Medicine, 2006
![Page 28: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/28.jpg)
0% 7.18% 0.83% 6.24% 1.52%
B
Ad1 prime(TW0)
4 weeks post prime(TW4 or 8)
Ad2 boost(TW 8 or 24)
4 weeks post boost(TW 12 or 28)
Final time point(TW 36 or 52)
CD8+
HLA
clas
s-I p
enta
mer
(KLS
GLGI
NAV
) High frequencies of HCV Specific CD8 T cells
Barnes et. al. Science Translational Medicine 2012
![Page 29: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/29.jpg)
• AdCh3NS and Ad6NS are highly potent (> 1400 SFU/million PBMC; IFN- ELISpot) following a single injection.
• At the highest dose all individuals responded to vaccination.
• The majority of subjects developed responses against multiple HCV proteins.
• Polyfunctional CD4 and CD8+ T cells are induced.• AdCh3NS and Ad6NS are safe and well tolerated at all
tested doses.
HCV Vaccine Healthy Volunteer Trial Summary
![Page 30: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/30.jpg)
= test immune responseW = week
HCV Prophylactic Vaccine Based on Sequential Use of AdCh3 and MVA with NS
AdCh32.5 x1010vp
MVA1.8x108pfu
W50W0 W8
• Cross reactivity of AdCh3 with human anti-adenovirus Abs is 12%
• MVA boosts well in Phase I trials• Double-blinded, randomized, placebo-controlled
two stage study.• Subjects: HCV Ab and RNA negative, active IDU’s
at high risk for HCV, 18 -45 y.o.• Two Sites (A. Cox/JHU & K. Page/UCSF)
![Page 31: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/31.jpg)
Endpoints
Primary• Safety of both vaccines• To determine if AdCh3NSmut1 and MVA-NSmut
HCV vaccines will reduce incidence of chronic HCV infection compared to placebo among HCV-uninfected IDUs.
Secondary• Immunogenicity compared to placebo when
administered to HCV uninfected IDUs
![Page 32: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/32.jpg)
Exploratory Endpoints
• Does it reduce the incidence of primary infection?
• Does it protect better against gt1b than others?
• Does it reduce the peak magnitude or duration of viremia in those infected?
![Page 33: The Immune Response to HCV and HCV Vaccine Development](https://reader035.vdocuments.site/reader035/viewer/2022062310/56815dff550346895dcc3f5e/html5/thumbnails/33.jpg)
GI Unit (& ID)Daniela KroyDonatella CiuffredaDavid WolskiJulian Schulze z. W.Garrett HauckJennifer CooperriderStephanie KulagaArthur KimJasneet AnejaLeslie Prince
Joe MisdrajiMichelle Tomlinson
Ray Chung
Oswaldo Cruz Inst., RdJLia Lewis
Lemuel Shattuck Hosp.Barbara McGovern
Oxford UniversityEllie Barnes
JHUAndrea Cox
FUNDINGNIH U19 AI082630NIH U19 AI066345Dana Foundation